The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide—the active ingredient in Eli ...

The U.S. Food and Drug Administration on Thursday found that there was no longer a shortage of Eli Lilly's blockbuster weight ...

Although an FDA drug shortages website lists all doses of both Wegovy and Ozempic as available, the agency said they are ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

This came after Eli Lilly and Company (India) presented the justification for Cmax values at a 90% confidence interval based ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / ...

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

tirzepatide. Because of this, the drugs have similar side effects. Ozempic’s active ingredient is semaglutide. Zepbound, Mounjaro, and Ozempic each come as prefilled, single-dose injection pens.